Changshan Pharmaceuticals: First subject enrollment has not yet been completed.

An investor asked Changshan Pharmaceuticals on the interactive platform: Now that the supplementary materials for abenatide have been submitted, will the company next focus on advancing the Phase I clinical trial of ebnatide as a weight-loss drug? On October 12, the company responded that it has submitted the supplementary materials for ebnatide's diabetes indication and will continue to actively cooperate with the CDE review process. For its Phase I clinical trial for the weight-loss indication, the relevant work is being orderly prepared, and the first subject has not yet been enrolled. The company has consistently steadily advanced the relevant clinical trials. New drug research and development is affected by multiple factors and involves uncertainty. If major R&D progress is achieved in the future, the company will strictly fulfill its information disclosure obligations in a timely manner in accordance with regulatory rules.